| car t therapy in multiple myeloma: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t therapy in multiple myeloma: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t therapy in multiple myeloma: Multiple Myeloma Morie A. Gertz, S. Vincent Rajkumar, 2013-10-01 This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment. |
| car t therapy in multiple myeloma: Stem Cells – From Hype to Real Hope Khawaja Husnain Haider, Salim Aziz, MD, 2018-12-17 This book is a compilation of the bench experience of leading experts from various research labs involved in the cutting edge area of research. The authors describe the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development, highlighting the shift from a conventional symptomatic treatment strategy to addressing the root cause of the disease process. The book is a continuum of the previously published book entitled Stem Cells: from Drug to Drug Discovery which was published in 2017. |
| car t therapy in multiple myeloma: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| car t therapy in multiple myeloma: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| car t therapy in multiple myeloma: Total Marrow Irradiation Jeffrey Y. C. Wong, Susanta K. Hui, 2021-03-01 This book, written by a team of international experts, concisely reviews the rationale and clinical application of image-guided total marrow irradiation, a rapidly emerging area in radiation oncology and hematopoietic cell transplantation. The aim is to provide the practicing radiation oncologist, hematologist, medical physicist, and bone marrow transplant researcher with a fundamental understanding of key aspects and an appreciation of the increasing significance of total marrow irradiation as conditioning for bone marrow transplantation. Detailed attention is paid to the impacts of recent advances in radiation therapy technology, functional PET and MRI, and understanding of the response of bone marrow to radiation. Full consideration is also given to the ways in which technological advances in image-guided radiation therapy have created new opportunities to treat bone marrow transplant patients with limited transplant options due to advanced disease, age, or co-morbidities. Further topics covered include the ways in which cancer stem cells and the marrow microenvironment influence response to radiation therapy and the implementation of new-generation predictive radiobiologic factors in the clinic. |
| car t therapy in multiple myeloma: HIV-1 Latency Guido Silvestri, Mathias Lichterfeld, 2018-10-11 This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing targeted interventions to reduce HIV-1 persistence during antiretroviral therapy. Specific chapters address the molecular mechanisms that govern and regulate HIV-1 transcription and latency; assays and technical approaches to quantify viral reservoirs in humans and animal models; the complex interchange between viral reservoirs and the host immune system; computational strategies to model viral reservoir dynamics; and the development of therapeutic approaches that target viral reservoir cells. With contributions from an interdisciplinary group of investigators that cover a broad spectrum of subjects, from molecular virology to proof-of-principle clinical trials, this book is a valuable resource for basic scientists, translational investigators, infectious-disease physicians, individuals living with HIV/AIDS and the general public. |
| car t therapy in multiple myeloma: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| car t therapy in multiple myeloma: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| car t therapy in multiple myeloma: Co-signal Molecules in T Cell Activation Miyuki Azuma, Hideo Yagita, 2019-11-22 This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science. |
| car t therapy in multiple myeloma: Drug Resistance in Leukemia & Gert-Jan L. Kaspers, 1993-01-01 The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols. |
| car t therapy in multiple myeloma: Heparanase Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan, 2020-04-09 Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology. |
| car t therapy in multiple myeloma: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| car t therapy in multiple myeloma: Update on Multiple Myeloma Khalid Ahmed Al-Anazi, 2019 This book is a comprehensive overview of the recent developments in the clinical and research fields of multiple myeloma. It is divided into three main sections that cover a wide range of topics, including: epidemiology and pathogenesis of the disease, genetic targets and pathways, resistance to novel therapies, angiogenesis and anti-angiogenesis, hematopoietic stem cell transplantation, role of radiology and radiotherapy in myeloma, infectious complications, and management of multiple myeloma in resource-poor countries. |
| car t therapy in multiple myeloma: Medical Masterclass John D. Firth, Sivakumar Sathasivam, Greg Heath, David Horton, 2018 |
| car t therapy in multiple myeloma: Principles and Practice of Palliative Care and Supportive Oncology Ann M. Berger, John L. Shuster, Jr., Jamie H. Von Roenn, 2012-12-03 Unlike other textbooks on this subject, which are more focused on end of life, the 4th edition of Principles and Practice of Palliative Care and Supportive Oncology focuses on supportive oncology. In fact, the goal of this textbook is to provide a source of both help and inspiration to all those who care for patients with cancer. Written in a more reader-friendly format, this textbook not only offers authoritative and up-to-date reviews of research and clinical care best practices, but also practical clinical applications to help readers put everything they learn to use. |
| car t therapy in multiple myeloma: The European Blood and Marrow Transplantation Textbook for Nurses Michelle Kenyon, Aleksandra Babic, 2018-03-14 This book is open access under a CC BY 4.0 license. This textbook, endorsed by the European Society for Blood and Marrow Transplantation (EBMT), provides adult and paediatric nurses with a full and informative guide covering all aspects of transplant nursing, from basic principles to advanced concepts. It takes the reader on a journey through the history of transplant nursing, including essential and progressive elements to help nurses improve their knowledge and benefit the patient experience, as well as a comprehensive introduction to research and auditing methods. This new volume specifically intended for nurses, complements the ESH-EBMT reference title, a popular educational resource originally developed in 2003 for physicians to accompany an annual training course also serving as an educational tool in its own right. This title is designed to develop the knowledge of nurses in transplantation. It is the first book of its kind specifically targeted at nurses in this specialist field and acknowledges the valuable contribution that nursing makes in this area. This volume presents information that is essential for the education of nurses new to transplantation, while also offering a valuable resource for more experienced nurses who wish to update their knowledge. |
| car t therapy in multiple myeloma: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| car t therapy in multiple myeloma: Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders Morie A. Gertz, Philip R. Greipp, 2003-11-24 This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease aspects from pathogenesis to most recent therapy are covered. The text originates from the Mayo Clinic, the world's most experienced institution in plasma cell disorders. Comprehensive treatise on all plasma cell disorders from the gene level to treatment of emergencies Chapters are uniformly organized for easy data access All authors are important authorities in their field with extensive clinical experience |
| car t therapy in multiple myeloma: Immunologic Concepts in Transfusion Medicine Robert W Maitta, 2019-08-27 Immunological Concepts in Transfusion Medicine provides a thorough discussion of the immune aspects of blood component transfusion, with in-depth information on the intricacies of immune responses to blood components and the immune processes that may be initiated in response to blood exposure. Written to increase knowledge and awareness of immune challenges such as alloimmunization and transfusion-related acute lung injury, this title bridges current basic scientific discoveries and the potential effects seen in blood recipients. - Complies the knowledge and expertise of Dr. Robert Maitta, an expert in immune responses and antibody function/structure studies. - Helps clinicians in the daily practice of caring for patients in need of transfusion support, as well as physicians in training when considering utilizing blood transfusions in a limited scope or in the setting of massive transfusion. - Includes an immunology primer as an introduction to in-depth chapters covering allergic immune reactions to blood components, transfusion-related immunomodulation, fetal and neonatal alloimmune thrombocytopenia and neonatal neuthropenia, complications of haploidentical and mismatched HSC transplantation, chimeric antibody receptor therapies, and much more. - Consolidates today's available information on this timely topic into a single, convenient resource. |
| car t therapy in multiple myeloma: Multiple Myeloma and Other Plasma Cell Neoplasms Meletios A. Dimopoulos, Thierry Facon, Evangelos Terpos, 2018-02-16 This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. |
| car t therapy in multiple myeloma: Allogeneic Stem Cell Transplantation Hillard M. Lazarus, Mary J. Laughlin, 2010-03-02 Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation. |
| car t therapy in multiple myeloma: The Emperor of All Maladies Siddhartha Mukherjee, 2011-08-09 Winner of the Pulitzer Prize and a documentary from Ken Burns on PBS, this New York Times bestseller is “an extraordinary achievement” (The New Yorker)—a magnificent, profoundly humane “biography” of cancer—from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence. Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and a biographer’s passion. The result is an astonishingly lucid and eloquent chronicle of a disease humans have lived with—and perished from—for more than five thousand years. The story of cancer is a story of human ingenuity, resilience, and perseverance, but also of hubris, paternalism, and misperception. Mukherjee recounts centuries of discoveries, setbacks, victories, and deaths, told through the eyes of his predecessors and peers, training their wits against an infinitely resourceful adversary that, just three decades ago, was thought to be easily vanquished in an all-out “war against cancer.” The book reads like a literary thriller with cancer as the protagonist. Riveting, urgent, and surprising, The Emperor of All Maladies provides a fascinating glimpse into the future of cancer treatments. It is an illuminating book that provides hope and clarity to those seeking to demystify cancer. |
| car t therapy in multiple myeloma: Report to the Congress, Medicare Payment Policy Medicare Payment Advisory Commission (U.S.), 1998 |
| car t therapy in multiple myeloma: Verbal Perseveration Jacqueline Ann Stark, 2007 Introductory textbooks on neurogenic communication disorders associated with aphasia and brain injury do not provide full documentation of the pervasive influence of perseveration in the diagnosis and treatment of clients with severe language processing deficits. This special issue of Aphasiology aims to revives the profound interest in verbal perseveration observed in the classical German literature between 1890 and 1931. Various aspects of the phenomenon of perseveration are addressed in this issue. When and under what circumstances do perseverations occur? What are the characteristics of perseverative errors and how do they relate to non-perseverative sound and word errors? The papers share a common goal, namely to understand the origin of the phenomenon 'perseveration' in healthy subjects and clients with brain damage and injury. An overarching claim throughout the papers is that perseveration reflects the client's primary language processing deficits. |
| car t therapy in multiple myeloma: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice MiKaela M. Olsen, Kristine B. LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2022 Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice-- |
| car t therapy in multiple myeloma: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| car t therapy in multiple myeloma: Cancer Immunotherapy Principles and Practice Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola, 2017 Part 1: Intratumoral Signatures Associated With Immune Responsiveness |
| car t therapy in multiple myeloma: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| car t therapy in multiple myeloma: Natural Killer Cells Srinivas S. Somanchi, 2016-05-13 This volume contains collection of Natural Killer Cell methodologies relevant for both basic and translational research. These methodologies present new developments in the natural killer (NK) cell field, such as understanding the influence of NK cells metabolism on its function, identifying complexity of NK cell subsets through mass cytometry, and determining the emergence of memory NK cells in murine model of MCMV infection. Methods that study NK cell migration and cytotoxicity through endpoint analysis or live single cell imaging are also discussed. Chapters also describe methods pertaining to translational application of NK cells, such as ex vivo expansion of NK cells on K562 cell lines genetically modified to express either membrane bound IL-15 or membrane bound IL-21, large scale NK cell culture, current techniques for engineering NK cells to express chimeric antigen receptors or chemokine receptors using retroviral vectors, electroporation of mRNA, and the natural phenomenon of trogocytosis. Written in the highly successful Methods in Molecular Biology series format, these chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, Natural Killer Cells: Methods and Protocols is a valuable resource for researchers who not only want to understand mechanisms that govern NK cell behavior and diversity, but also for those who want to understand how to systematically evaluate NK cells for adoptive immunotherapy applications. |
| car t therapy in multiple myeloma: The EBMT Handbook Nicolaus Kröger, Mohamad Mohty, Carlo Dufour, 2020-10-08 This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills. This work was published by Saint Philip Street Press pursuant to a Creative Commons license permitting commercial use. All rights not granted by the work's license are retained by the author or authors. |
| car t therapy in multiple myeloma: CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America, E-Book Caron A Jacobson, Parth S. Shah, 2023-10-12 In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). - Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. - Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| car t therapy in multiple myeloma: Car T-Cell T, an Issue of Hematology/Oncology Clinics of North America: Volume 37-6 Caron A. Jacobson, Parth S. Shah, 2023-12-28 In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| car t therapy in multiple myeloma: Immunotherapy in Multiple Myeloma Nicola Giuliani, Fabio Malavasi, Vito Pistoia, 2019-11-26 |
| car t therapy in multiple myeloma: Fast Facts: CAR T-Cell Therapy Richard J. Buka, Ankit J. Kansagra, 2021-02-28 Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field. Table of Contents: • CAR T cells • Clinical application • Practical aspects • Future directions |
| car t therapy in multiple myeloma: Novel Agents for Multiple Myeloma Claudio Cerchione, Hans C. Lee, Giovanni Martinelli, María-Victoria Mateos, Kenneth Anderson, 2024-05-07 Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. It accounts for approximately 1.8% of all hematologic and solid cancers and slightly > 15% of hematologic malignancies in the United States. MM is typically sensitive to different classes of cytotoxic drugs, both as frontline treatment and as treatment for relapsed disease. Unfortunately, even if responses are typically durable, nowadays MM is not considered curable with current approaches. However, MM survival rates have been brilliantly improved thanks to the introduction of novel agents: patients diagnosed after 2010 have had higher rates of novel therapy use and better survival outcomes compared with those of earlier years. Most relevant therapeutic advances over the past decades has been the introduction of novel therapies, such as immune-modifying agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), adopted with or without stem cell transplantation. |
| car t therapy in multiple myeloma: Engineered Targeted Cancer Immunotherapies Massimo Fantini, Roberto Bei, 2022-08-01 |
| car t therapy in multiple myeloma: The Novel Engineering Strategies and Clinical Progress of Solid Tumor in CAR-T Cell Therapy Ken Young, Zheming Lu, Wenbin Qian, 2022-08-18 |
| car t therapy in multiple myeloma: Translation of genetically engineered T cells in cancer immunotherapy Shao-An Xue, He Huang, Hakim Echchannaoui, Ralf-Holger Voss, 2023-10-06 |
r/Cars - For Car Enthusiasts - Reddit
r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY guides, advice, stories, …
Former CarMax employee here. If you plan to go in for an ... - Reddit
Feb 3, 2021 · Where younger an estimated value and when you come in our car buyer puts in his notes and we show you side by side. Where you thought you were and didn't mention that …
How much do car salesmen REALLY make? : r/askcarsales - Reddit
Apr 26, 2022 · Is 6 figures in car sales the norm? EDIT: 25M, single, no kids. Currently in civil engineering with $78k salary in LCOL area (central texas). Seems like folks are making well …
Hoseheadforums.com Home
Aug 17, 2013 · Bodnar Motorsports building new car for 2019 viewed (10751) Wicked Energy Gum to Sponsor the Northwest Focus Midget Series viewed (8765) Heartland Motorsports Park …
best places to search for used cars : r/cars - Reddit
Sep 7, 2018 · r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY …
Car dealership scratch-off mailer scam (Update) : r/Scams - Reddit
Mar 12, 2019 · I posted a couple of days ago about a scratch-off contest mailer that I had received from a local car dealership. My "game piece" seemed to indicate that I had won the Grand …
Nothing Under - Reddit
r/NothingUnder: Dresses and clothing with nothing underneath. Women in outfits perfect for flashing, easy access, and teasing men.
What’s the best auto insurance? : r/Insurance - Reddit
I also know that being young and driving a newer car is the reason behind all this, but any advice/tips about all this is much needed! Is the monthly rate really normal for someone my …
HoseHeads Sprint Car General Forum - Oval Track Racing Forums
4 days ago · Forum: HoseHeads Sprint Car General Forum Moderators: dirtonly / dmantx / hosehead First
I've been scouring the internet for a working download link to
Aug 26, 2023 · 31 votes, 30 comments. 36K subscribers in the E90 community. Hub for all BMW 3 series, 2006-2013. Anyone is welcome!
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, …
Oct 30, 2021 · CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma Luciano J. Costa, MD, PhD, 1 Yi Lin, 2 R. Frank …
Considering CAR-T Cell Therapy - themmrf.org
Understanding CAR T-Cell Therapy for Multiple Myeloma April 2025. Tech Support 1-719-234-7952. Resources •Resource tab includes –Speaker bios –Copy of the slide presentation …
Neutrophil activation and clonal CAR-T re-expansion ... - Nature
B-celllymphoma2 patientsreceivinganti-CD19CAR-Ttherapy,and41% of multiple myeloma (MM) 3 patients infused with anti-BCMA CAR-T. CRS is theoretically an indispensable in flammatory …
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or …
May 8, 2019 · CAR T-Cell Therapy in Multiple Myeloma M ultiple myeloma remains an in-curable plasma-cell cancer. Advance-ments in treatment, including the intro-duction of …
CAR-T for Multiple Myeloma - asset.researchtopractice.com
CAR-T for Multiple Myeloma Surbhi Sidana, MD Associate Professor of Medicine Stanford University Jan 2025. ... therapy including PI, IMiD and anti-CD38 antibody Ide-cel: March 2021 …
Bendamustine vs. fludarabine/cyclophosphamide …
BCMA CAR-T therapy (ide-cel and cilta-cel) at two centers, Stanford University and City of Hope, from May 2021 to December 2022, with follow-up data collected through June 30, 2023.
A Roadmap for Relapse/Refractory Multiple Myeloma Referral
Ailawadhi S et al. Optimizing the CAR T-Cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma Myeloma Leuk. 2024;24(5):e217-25. ...
Immune effector cell-associated enterocolitis following …
We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall …
Potent in vivo transduction by iGPS particles generates CAR T …
CAR T cells have been transformative for multiple myeloma patients 3 Mateoset al. Haematologica. 2022 Jagannath et al. Blood Cancer J. 2021 Carvykti ... Kelonia’s …
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed …
antigen–directed CAR T-cell therapy that is produced by means of lentiviral trans- ... A 51-year-old man with multiple myeloma (diag - nosed in December 2019) and a high-risk cyto-genetic ...
Extramedullary disease but not paraskeletal disease portends …
Chimeric antigen receptor (CAR) T cell therapy is effective for multiple myeloma (MM), yet patients with plasmacytomas, either paraskeletal disease (PSD) or extramedullary disease …
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed …
a BCMA-directed CAR T cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma: updated results from KarMMa Larry D. Anderson, Jr, 1 ... RRMM, …
942 Chimeric Antigen Receptor Therapy for Multiple Myeloma
2 6. Have not received prior FDA approved, BCMA-directed, chimeric antigen receptor T therapy. *Relapsed Multiple Myeloma Relapse requires 1 or more of the following direct indicators of …
Cellular dynamics following CAR T cell therapy are associated …
CAR T cells in multiple myeloma (MM) are still emerging. BCMA is an attractive target for CAR T cell therapy in MM due to its high and selective expression on malignant plasma cells. Early …
Long-term safety and efficacy of the fully human CAR-T …
Table S1. Long-term outcomes of patients with relapsed and/or refractory multiple myeloma receiving anti-BCMA CAR-T therapy Study Number of patients CAR name Trial phase Median …
CAR&T cells in the treatment of multiple myeloma: an
multiple myeloma, CAR, T cell, immunotherapy, CAR-T 1 Introduction Multiple myeloma (MM) is a malignant disease of plasma cells that accounts for ... BCMA-CAR T cell therapy has achieved …
Ciltacabtagene Autoleucel: Insights on Chimeric Antigen …
Multiple myeloma (MM) is a relatively rare malignancy of plasma cells that accumulate in the bone marrow, with an estimated 34,920 new cases and 12,410 deaths in ... around CAR T therapy …
Prognostic significance of PET/CT for CAR T cell therapy in …
myeloma after CAR T‐cell therapy. Blood Cancer J. 2024; 14:214. 22. LeeH,DuranteMA,SkergetS,etal.ImpactofsolubleBCMAandnon‐T‐ cell factors on refractoriness …
CAR T-cell therapy in multiple myeloma: more room for …
Multiple myeloma (MM), which accounts for 10% of ... CAR T-cell therapy in MM CAR T research in myeloma is still at its infancy, comparatively to lymphoma and ALL (Fig. 1). The most
Enhanced CAR-T cell function and mitochondrial fitness from …
The introduction of chimeric antigen receptor T (CAR-T) cells tar-geting B cell maturation antigen (BCMA) has completely altered the treatment paradigm for patients with relapsed and …
Anti-GPRC5D CAR-T Cell Therapy for Multiple Myeloma
Anti-GPRC5D CAR T-cell is a CAR-T cell therapy that targets GPRC5D for the treatment of multiple myeloma. When the CAR specifically binds to GPRC5D on the multiple myeloma …
The Challenges and Future of CAR T-Cells for Treating …
These ideas were gathered through an in-depth exploration of CAR T -cell therapy for multiple myeloma discussing the current challenges and potential solutions within the field. Introduction …
Transplantation and Cellular Therapy - astctjournal.org
Despite the success of chimeric antigen recept or (CAR) T-cell therapy for relapsed or refrac-tory multiple myeloma (RRMM), failure after CAR T-cell therapy remains an unmet medical need. …
How to Treat Relapsed/Refractory Multiple Myeloma in 2020
Multiple Myeloma in 2020 . This activity is provided by the Annenberg Center for Health Sciences at Eisenhower and developed ... Bispecific antibodies or CAR T -cell therapy. Thomas G. …
P-BCMA-ALLO1 a non-viral allogeneic anti-BCMA CAR T …
anti-BCMA CAR T therapy with potent anti-tumor function for the treatment of multiple myeloma Maximilian Richter, Stacey A. Cranert, Yening Tan, Min Tong, Christine Domingo, Elvira …
CAR T cell therapy in Multiple Myeloma, where are we now …
CAR T cells, ciltacabtagene autoleucel, CRS, ICANS, idecabtagene vicleucel, multiple myeloma, refractory, relapsed Novelty statements What is the new aspect of your work? We summarize …
多発性骨髄腫におけるCAR-T細胞療法 - J-STAGE
Table 1．Anti-BCMA CAR-T cell therapy in relapse refractory multiple myeloma Reference Trial CAR N Median lines of therapy Dose of CAR＋ T Cells Overall response rate Median PFS …
Successful BCMA CAR-T Therapy for Multiple Myeloma …
demonstrated that BCMA CAR-T cells are effective and safe in this patient population. Keywords: multiple myeloma, central nervous system, chimeric antigen receptor (CAR T), …
Is Australia ready, willing and able? - Evohealth
The introduction of CAR T-cell therapy for multiple myeloma could quadruple the number of patients seeking access to care compared to current levels [6]. Up to 97% of multiple myeloma …
Press release CONTACT - drreddys.com
Press release Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma Bengaluru & …
An alternative fully human anti-BCMA CAR-T shows response …
directed CAR-T therapy were analyzed, and the median PFS for the ... multiple myeloma, including protease inhibitors and immunomodulators, and have disease progression within 60 …
MM-183 - Clinical Lymphoma, Myeloma & Leukemia
MM, CAR-T cell therapy, cilta-cel, multiple myeloma, Phase I/II MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta …
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory …
CAR-T structure, n (%) 0.192 Murine 18 (72.0) 20 (55.6) Fully human 7 (28.0) 16 (44.4) EMM, extramedullary myeloma; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; …
BCMA-BBZ-OX40 CAR-T Therapy Using an Instant …
WangfiT, etal Iunother Cancer 202412e009476 doi101136itc-2024-009476 1 Open access BCMA- BBZ- OX40 CAR- T Therapy Using an Instant Manufacturing Platform in Multiple …
Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in …
Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases Wai Lun Will Pak, Natalie …
Autologous stem cell boost improves persistent immune …
undergoing B-cell maturation antigen (BCMA) CAR T cell therapy for multiple myeloma (MM), a significant percentage have exhibited persistent ICAHT [2, 4–6, 21]. Severe and prolonged
CAR-T cell therapy in multiple myeloma: Current limitations …
Feb 20, 2023 · CAR-T cell therapy. Thus, many research efforts are underway to explore effective strategies. 2 Resistance to anti-BCMA CAR-T cell therapy in multiple myeloma and potential …
Transplantation and Cellular Therapy - astctjournal.org
patients with relapse refractory multiple myeloma (RRMM) receiving anti-BCMA CAR-T therapy. We included all patients treated with commercial CAR-T therapy for RRMM between 5/1/2021 …
Matching-Adjusted Indirect Treatment Comparison to Assess …
May 28, 2022 · tor T-cell (CAR-T) therapies, have emerged for treatment of patients with relapsed or refractory multiple myeloma (RRMM) who have exposure to available therapies. …
Long-term safety and efficacy of the fully human CAR-T …
Original Article Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma Qiuxia Yu, 1,6Di Wang, Zhe Li, 1Ning ...
Outcomes in patients with multiple myeloma receiving …
B38M CAR-T therapy, 32 patients received a first salvage treatment, including PI-based combination therapy (n = 15), a second BCMA CAR-T (n =10) and combination chemo …
Emerging therapies for relapsed/refractory multiple …
making it an attractive target for CAR-T therapy [43]. e CAR-T candidate which has currently advanced the furthest in clinical development is idecabtagene vicleu-cel, a recent FDA …
Mechanisms of resistance to CAR-T cell therapy in multiple …
underlying CAR-T resistance, including antigen escape, immunosuppression, and CAR-T cell exhaustion, is essential for enhancing the long-term efficacy of this therapeutic approach. This …
CAR-T cell therapy in multiple myeloma: Current limitations …
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies Xiaomin Zhang1, Hui Zhang2, Huixuan Lan3, Jinming Wu1 and Yang Xiao4* 1Department of …
Molecular mechanisms promoting long-term cytopenia after …
May 22, 2024 · Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma Maria Luisa Palacios-Berraquero1,†,&, Paula Rodriguez-Marquez2,8,†, …
Engineered T-Cell Therapy for Multiple Myeloma Prior …
Source: 2016 International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma BRefractory Multiple Myeloma Refractory multiple myeloma is defined as …
Multiple Myeloma Immunotherapies – Targets, Sequencing, …
Multiple Myeloma Immunotherapies – Targets, Timing, Sequencing, Reusing Alfred Garfall, MD Assocate Professor of Medicine. 1 March 2025. MCW 2025 Controversies in Hematologic …
Effectiveness of Bridging Therapy Corresponds to Improved …
After Receiving CAR-T Therapy in the Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma The correlation between tumor burden reduction …
A phase I open-label single-arm study of dual targeting …
CD19 is expressed on both multiple myeloma cells and their progenitors2, making it a valid therapeutic target to treat multiple myeloma MOA of GC012F for MM BCMA-19 R-T i-Fv ...
Selinexor-Containing Regimens for the Treatment of Patients …
effective dose of CAR-T cell therapy (>108CAR-positive cell targeting B-cell maturation antigen for MM prior to being enrolled in a trial using a selinexor-containing regimen. •This is the first …
